Biography for Nick Paul Taylor
Nick Taylor, UK Correspondent
Nick Taylor is a freelance journalist with more than six years' experience of reporting on the global biopharma industry. Since graduating with a biology degree from the University of York, Nick has written for numerous healthcare publications, including Nature BioPharma Dealmakers, Life Science Leader and Outsourcing-Pharma. You can contact him at email@example.com and follow him on Twitter at @NickPaulTaylor.
Articles by Nick Paul Taylor
Faced with the challenge of how to handle data from the 100,000 exomes it intends to sequence, Regeneron has struck a deal with DNAnexus to access cloud-based infrastructure.The biotech is working with DNAnexus through the Regeneron Genetics Center it established for the sequencing project.
The acquisition tightens BBK's ties to the team that helped to develop its patient and site engagement mobile app, My Clinical Study Buddy.
Genomics England has dropped two-thirds of the candidates to provide variant annotation and clinical interpretation services to the 100,000 Genomes Project after reviewing the first round of responses.
The genetic research community is about to get access to a lot of data. On October 20, two public databases generated by whole-genome and exome sequencing at multiple research institutions will be unveiled.
Novo Nordisk is reportedly set to unveil details of an IPO of its IT services business NNIT in the coming days. The Danish drugmaker has spent most of 2014 assessing whether to spin off the unit as an independent company.
Increased reliance on software to support aspects of drug development has simplified many tasks but created the possibility that an IT glitch could have far-reaching implications. Now, the European Medicines Agency is to discuss whether this situation has already happened.
The National Institutes of Health has kicked off its Big Data to Knowledge (BD2K) initiative with an initial $32 million in funding. Harvard, Stanford and other universities received some of the cash to set up Centers of Excellence for Big Data Computing, each of which will tackle a different aspect of turning numbers into biomedical understanding.
The list of life science data projects underpinned by Google keeps getting longer. Having signed up to the BRAIN Initiative last week, Google has now teamed up with ISB and SRA International to work on a project for the National Cancer Institute.
With report after report finding flaws in the data security practices of healthcare and life science organizations, Exostar has decided to accelerate its expansion into the sector. And the company has snagged funding from the Merck Global Health Innovation Fund to support its plans.
Accenture has joined with some big names for its R&D analytics platform. Eisai, Merck and Pfizer have signed up to collaborate on further development of the system, which is built on a mix of technologies from Accenture and Oracle.